October 25, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
DUBLIN, Ireland (October 25, 2024) – Trinity Biotech plc (Nasdaq: TRIB), a commercialstage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market.